Japan's Shionogi readies Covid-19 vaccine for December trial

Shionogi chief executive Isao Teshirogi said the company plans to put its vaccine candidate into Phase 1 clinical trials in December. - Reuters

TOKYO (Reuters): Shionogi & Co is planning clinical trials by year-end for what may be one of Japan's first domestically produced Covid-19 vaccines to reach the market, as the globe races to secure enough doses to battle the pandemic.

The company plans to put its vaccine candidate into Phase 1 clinical trials in December and shift into Phase 2 by January and apply for tentative approval from the government, Shionogi chief executive Isao Teshirogi told Reuters in an interview.